Skip to Content
  • Previous Rank-
  • Revenue 3 Yr Annual Growth Rate46%
  • Revenue 3 Yr Growth Rank19
  • EPS 3 Yr Annual Growth Rate154%
  • EPS 3 Yr Growth Rank5
  • Total Return 3 Yr Annual Rate52%
  • Total Return 3 Yr Rank8

Supernus Pharmaceuticals is tackling what is, perhaps, the most difficult project in the life sciences sector—treating the diseases that afflict our brains, including epilepsy and migraines. In the second quarter of 2018, the firm’s revenues ballooned by more than 30% to $99.5 million, driven by greater sales of flagship drugs Oxtellar XR and Trokendi XR. The company’s latest earnings figures fell a bit short of Wall Street expectations, but that may not be of much concern given how hot the stock has been over the past five years: It has provided shareholders with a stunning 571% return.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
Rockville, Md.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
Jack Khattar
Websitehttp://www.supernus.com
Revenue and net income for the four quarters ended on or before April 30, 2018. Total return for the period ended June 29, 2018.

Revenue, Net Income

Revenue past four quarters ($M)$335
Net Income past four quarters ($M)$73

Growth Rates and Ranks

Revenue 3 Yr Growth Rank19
Revenue 3 Yr Annual Growth Rate46%
EPS 3 Yr Growth Rank5
EPS 3 Yr Annual Growth Rate154%
Total Return 3 Yr Rank8
Total Return 3 Yr Annual Rate52%
Beat S&P 500 (11.9%)
yes
P/E Ratio29